Nara Organics Recalls All Infant Formula Lots After Three Botulism Cases Confirmed Across Two States

Three confirmed infant botulism hospitalizations have triggered a full market withdrawal of Nara Organics Whole Milk Powdered Infant Formula, exposing a critical gap that QA directors in powdered formula manufacturing cannot afford to overlook: a voluntary recall proceeding without a single positive product test result.

FDA and CDC contacted Nara Organics on June 12, 2026, presenting epidemiological data linking three hospitalized infants in California, Washington, and Pennsylvania to Nara formula consumption. All three were treated with BabyBIG (Botulism Immune Globulin Intravenous); no deaths have been reported. The implicated lots are 709125280E14F2, 709125288E14F2, and 708125174E14F2, though the recall encompasses all 15 lot codes currently on the market across both the 700g (UPC 860013251901) and 400g (UPC 860013251918) SKUs.

The absence of confirmed Clostridium botulinum contamination in product testing does not reduce the regulatory or operational weight of this event. Under 21 CFR Part 110 and current GMP expectations for powdered infant formula, epidemiological linkage alone is sufficient to compel action, and FDA's rapid coordination with CDC signals the agency's intent to treat case clustering as actionable evidence pending laboratory confirmation. For plant heads, this is a direct reminder that environmental monitoring programs and incoming ingredient controls for spore-forming organisms must be robust enough to withstand scrutiny before an outbreak, not after.

Distribution ran nationally through Target retail locations, Target.com, and Nara.com between July 2025 and June 2026, a 12-month window that complicates lot traceability and consumer notification reach. The scale of the distribution channel, a major national retailer alongside direct-to-consumer e-commerce, also raises questions about the adequacy of existing recall communication procedures and whether CAPA frameworks were structured to handle multi-channel product retrieval at speed.

For QA leads, the CAPA documentation burden here is substantial: root cause investigation must account for raw material sourcing, processing environment controls, and post-fill handling across a production window spanning nearly a year, all while product testing has not yet returned a positive result. The ICH Q10 principle of continual improvement applies directly; if environmental monitoring did not flag a C. botulinum risk vector, the gap belongs in the CAPA record regardless of how the epidemiological investigation resolves.

The investigation by FDA, CDC, and state partners remains active, and the outcome of confirmatory product and environmental testing will determine whether this recall closes as a precautionary measure or escalates into a broader manufacturing controls review.

Source: U.S. Food and Drug Administration Recalls, Market Withdrawals and Safety Alerts via FDA.gov, June 13, 2026.